Eric B. Lev

Eric, who joined Ampersand in 2013, has over 22 years of middle-market healthcare investment experience. Eric’s current and past board seats include Biologos, Biosynth, CutisPharma, Genoptix, iuvo Biosciences, LakePharma, Nexelis, Nexcelom Biosciences, NuvinkaDx, P95 and Resolian. Before joining Ampersand, he spent seven years as a founding member of the investment team at Water Street Healthcare Partners. Prior to Water Street, Eric worked at Beckman Coulter and One Equity Partners. Eric holds a B.A. in Economics from Northwestern University and an M.B.A. from the University of Chicago.